Could your own tumor cells beat melanoma? new trial tests immune cell therapy
NCT ID NCT05098184
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a therapy made from a patient's own tumor-fighting immune cells (TILs) for advanced melanoma. Doctors take TILs from a tumor sample, grow them in the lab, and infuse them back after a short chemotherapy course. The study aims to see if this approach is safe and can shrink tumors in 50 people who have not responded to standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tumor-infiltrating lymphocytes (TILs)
- What this could lead to
- If successful, this could offer a new treatment option for advanced melanoma patients who have run out of standard therapies.
- What could go wrong
- This is a very early, small trial (50 people) focused on safety. The treatment may not shrink tumors, and side effects from the lymphodepletion regimen can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Tenth People's Hospital
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Patient's own immune cells fight advanced cancer?
- Can chemo and radiation steal fertility? a massive study aims to find out
- Can a new biologic drug shrink advanced melanoma tumors?
- Engineered immune cells take aim at Hard-to-Treat cancers
- Could a diabetes drug boost immunotherapy in advanced melanoma?
- New combo therapy takes on advanced cancers